Following the news of a license deal with Evofem Biosciences, Inc. (OTCQB: EVFM), shares of Windtree Therapeutics, Inc. (NASDAQ: WINT) saw a sharp increase. WINT stock was selling at $2.70 as of the most recent market check, representing a remarkable 59.48% rise.
PHEXXI Strategic Licensing Agreement
Windtree Therapeutics (WINT) has secured its position as the sourcing partner for Evofem’s FDA-approved contraceptive medicine, PHEXXI, by entering into a License and Supply Agreement.
Lactic acid, citric acid, and potassium bitartrate are the ingredients in this prescription vaginal gel, which provides women with a hormone-free, controllable method of contraception on demand. With yearly sales of over $19 million and the sale of over 96,000 boxes of 12 pre-filled applicators in 2024, PHEXXI has seen significant market expansion.
Lowering Manufacturing Costs for Global Expansion
Windtree wants to drastically lower the cost of producing PHEXXI by utilizing its current manufacturing network. As per the deal, WINT will serve as Evofem’s sourcing partner, discussing cost-cutting measures with pharmaceutical producers. Notwithstanding this collaboration, Evofem will continue to hold PHEXXI and pursue strategic alliances to further commercialize the drug in both domestic and foreign markets.
This partnership is in line with Windtree’s overarching business plan, which was revealed in January 2025 and calls for the company to become a profitable biotechnology company. With the deal with Evofem, the business takes the first step toward long-term success.
Enhancing Market Accessibility
In order to expedite the transfer of technology and supervise the manufacturing of first and validation batches in accordance with FDA rules, Windtree has already started talks with a pharmaceutical manufacturer. High production costs have been a significant obstacle for Evofem, impeding attempts at international commercialization.
This collaboration with Windtree is anticipated to allow Evofem to launch PHEXXI into price-sensitive international markets, where there is still a high demand for non-hormonal contraceptive choices, by significantly reducing the product’s per-box cost.
By taking this calculated step, both businesses want to increase access to PHEXXI and reaffirm their dedication to offering creative and reasonably priced healthcare options to women everywhere.